May 14, 2019 / 05:40PM GMT
Tazeen Ahmad - BofA Merrill Lynch, Research Division - VP
(technical difficulty) joining us. I am Tazeen Ahmad, I'm the Senior SMid Biotech analyst of Bank of America Merrill Lynch. Welcome to our Healthcare Conference. It's my pleasure to introduce the next presenting company, ACADIA Pharmaceuticals. With us from ACADIA at the podium is Steve Davis, CEO. Sitting next to me is Elena Ridloff, CFO of the company. And in the audience, we have Mark Johnson from IR. Steve's going to start off with a couple of slides just giving you an introduction to the company and what the company is focused on, and then we'll switch to Q&A right after that.
So with that, I'll turn it over to Steve.
Stephen R. Davis - ACADIA Pharmaceuticals Inc. - CEO & Director
Great. Thanks much, Tazeen, and good morning to each of you. I need to start just reminding all of us that the business of pharmaceutical development and commercialization has certain risks inherent in the business. Please see a copy of our most recent SEC filings for a description of risks that relate our
ACADIA Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers